Alfasigma, a pharmaceutical products wholesaler, completed the acquisition of Intercept Pharmaceuticals, a biopharmaceutical company, for $794m. “The acquisition of Intercept marks another important milestone in Alfasigma’s growth path, particularly with regard to the US market in which we have significant development objectives. Intercept represents a compelling fit with Alfasigma’s core business areas of gastroenterology and hepatology, and we believe that the transaction represents a transformational opportunity for both companies. We are excited to welcome Intercept employees and look forward to working together as we invest in the company to realize the full potential, to the benefit of patients,” Francesco Balestrieri, Alfasigma CEO.